H.R. 1266 — Combating Illicit Xylazine Act, as amended
Executive Summary
H.R. 1266, the 'Combating Illicit Xylazine Act,' addresses the escalating overdose crisis driven by xylazine (a veterinary tranquilizer often mixed with fentanyl) by classifying it as a Schedule III controlled substance. Crucially, the bill threads the needle between cracking down on illicit diversion and protecting legitimate veterinary access by creating specific exemptions for 'ultimate users' in animal care and delaying certain compliance burdens for manufacturers and practitioners. This bipartisan measure aims to give law enforcement the tools to prosecute illicit traffickers while preventing supply chain disruptions for agriculture and veterinary medicine.
Arguments For
- Provides law enforcement with necessary statutory authority to prosecute traffickers of 'tranq' (xylazine), which is increasingly driving fatal overdoses when mixed with fentanyl.
- Carefully protects the agricultural and veterinary sectors by exempting legitimate animal use from stringent Schedule III 'ultimate user' restrictions, avoiding political backlash from rural constituencies.
- Offers regulatory relief and transition periods for existing manufacturers, preventing immediate supply chain shocks for legitimate veterinary medicine.
Likely Supporters
Arguments Against
- Harm reduction advocates may argue that criminalizing xylazine could drive the illicit market toward even more dangerous synthetic adulterants.
- Despite exemptions, the Schedule III designation will inevitably increase administrative and compliance burdens on veterinarians and rural pharmacies.
- Directing the Sentencing Commission to review penalties may raise concerns among criminal justice reform advocates about expanding the War on Drugs and increasing incarceration rates.
Likely Opponents
📋 Key Provisions
- Classifies xylazine as a Schedule III controlled substance under the Controlled Substances Act.
- Amends the definition of 'ultimate user' to exempt veterinarians, farmers, and animal control agencies using xylazine for legitimate animal care.
- Mandates the DEA's ARCOS system track xylazine to monitor diversion.
- Directs the U.S. Sentencing Commission to review and amend penalties for illicit xylazine trafficking.
- Provides transition periods for manufacturers and practitioners to comply with Schedule III security, labeling, and registration requirements.
search
Verification Guide
BETA
expand_more
Don't trust AI? Don't worry, neither do I. Verify the claims yourself.
Adds xylazine to Schedule III of the Controlled Substances Act.
"Schedule III of section 202(c)"
Exempts current manufacturers from Schedule III capital expenditure security upgrades.
"required to make capital expenditures"
Delays labeling and packaging requirements for one year.
"until the date that is 1 year"
Requires an initial report to Congress within 18 months on illicit xylazine use.
"Not later than 18 months after"